Pacira | PCRX - Net Income

Stock Price
23.45
Daily Change
-0.01 -0.04%
Monthly
14.39%
Yearly
-7.97%
Q1 Forecast
22.50

Pacira reported $5.43M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
Assertio Holdings USD -2.92M 753K Sep/2024
Astellas Pharma JPY 100.38B 21.17B Dec/2025
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Cara Therapeutics USD -4.91M 2.77M Mar/2025
Coherus Biosciences USD -56.57M 5.87M Mar/2025
Heron Therapeutics USD -4.85M 4.39M Sep/2024
Ironwood Pharmaceuticals USD 3.19M 457K Dec/2024
J&J USD 5.12B 36M Dec/2025
Ligand Pharmaceuticals USD 117.27M 112.43M Sep/2025
Nektar Therapeutics USD -37.06M 15.31M Sep/2024
Novo Nordisk DKK 26.89B 388M Dec/2025
Omeros USD -32.23M 23.81M Sep/2024
Pacira USD 5.43M 10.28M Sep/2025
Perrigo USD 7.5M 15.9M Sep/2025
Pfizer USD -1.65B 5.19B Dec/2025
Supernus Pharmaceuticals USD -45.12M 67.62M Sep/2025
Teva Pharmaceutical Industries USD 480M 47M Dec/2025
Xeris Pharmaceuticals USD 621K 2.55M Sep/2025
Xoma USD -17.24M 33.23M Sep/2024
Zoetis USD 603M 118M Dec/2025